Does Medicare Cover Zepbound for Sleep Apnea?
Zepbound (tirzepatide) gained FDA approval for obstructive sleep apnea in December 2024, allowing Medicare drug plans to treat it as a medically accepted indication. Whether the medication is actually paid for, however, depends on each Part D plan’s 2026 formulary, utilization rules, and your documentation.
Medicare Part D can cover Zepbound for obstructive sleep apnea (OSA) now that the drug has an FDA-labeled indication, but coverage is not automatic. Each Part D plan decides whether to list Zepbound on its 2026 formulary, often placing it on a higher tier and requiring prior authorization that confirms you meet the FDA labeling and have tried standard OSA therapies. Submitting clear clinical notes, sleep-study results, and proof of CPAP intolerance greatly improves the odds of approval, and if you are denied you can appeal or use Lilly’s bridge program while the decision is reviewed.
- The FDA added OSA to Zepbound’s label on December 22 2024, making it a “medically accepted indication” under Medicare Part D.
- The 2026 standard Part D deductible is $615 and the out-of-pocket cap rises to $2,100 before cost sharing ends cms.gov.
- Part D plans often place new brand-name drugs like Zepbound on a Tier 3 or Tier 4 specialty tier with 25% coinsurance after the deductible.
- CMS research shows only a small minority of newly approved drugs are widely covered in their first Part D year, and most face prior authorization (Naci et al., 2022).
- You will usually need a recent sleep study, documented CPAP trial or intolerance, and a body-mass index (BMI) of 30 kg/m² or higher to pass prior authorization.
- If coverage is denied, you can appeal and use Eli Lilly’s GLP-1 Bridge program to receive up to 12 months of Zepbound at no cost while waiting for a final decision.
What Zepbound Is and Why the OSA Approval Matters
Zepbound is the brand-name injection of tirzepatide, a dual GIP/GLP-1 receptor agonist that lowers body weight and improves airway stability during sleep. The FDA granted a new indication for treating moderate-to-severe obstructive sleep apnea (OSA) with excess weight on December 22 2024, making OSA an on-label use rather than an off-label one. Because Medicare Part D only reimburses outpatient drugs for “medically accepted indications,” the label expansion opened the door for coverage.
Before the label change, Zepbound was covered only for Type 2 diabetes in limited cases. Now, plans can list Zepbound in the same way they list other OSA medicines such as modafinil. However, Part D plans still decide tier placement and restrictions individually, so coverage varies by ZIP code.
How Medicare Part D Decides Whether to Cover Zepbound
Part D plans have wide latitude to include or exclude newly approved drugs and to attach restrictions such as prior authorization or quantity limits. An analysis of 4,582 Part D formularies found that only a small share of new drugs in non-protected classes are widely covered in the year after FDA approval, and most face utilization management (Naci et al., 2022). Zepbound is in a non-protected class, so each plan’s pharmacy & therapeutics (P&T) committee votes on inclusion, tier, and restrictions.
Key factors committees weigh:
- Clinical evidence: Phase 3 trial data showing apnea-hypopnea index (AHI) reductions.
- Cost to plan: Zepbound’s wholesale acquisition cost (WAC) and available rebates.
- Therapeutic alternatives: CPAP, weight-loss surgery, and older weight-loss drugs.
- CMS guidance: Whether the agency flags Zepbound as a “selected drug” subject to IRA negotiations.
Because Zepbound is expensive and not in a protected class, most plans in 2026 list it on Tier 3 or Tier 4 and require prior authorization.
What Prior Authorization for Zepbound Usually Requires
Prior authorization (PA) asks your prescriber to prove you meet the FDA label and have tried standard therapy. While every plan writes its own form, most share the following checkpoints:
| Common PA Question | Documentation Needed | Why It Matters |
|---|---|---|
| Diagnosis of moderate-to-severe OSA? | Sleep study with AHI ≥ 15 | Confirms on-label use |
| Excess weight? | BMI ≥ 30 kg/m² recorded within 12 months | Matches FDA criteria |
| CPAP tried and failed? | Chart note showing intolerance or inadequate AHI reduction after ≥90 days | Ensures first-line therapy attempted |
| Other weight-loss meds attempted? | Medication history print-out | Shows step therapy compliance |
| Prescriber specialty? | Sleep medicine, pulmonology, or endocrinology NPI | Plans may reject primary-care only |
Submit the PA package electronically when possible, because digital submissions shorten review times from weeks to days at many PBMs.
How Much You Could Pay for Zepbound Under Medicare in 2026
Your out-of-pocket cost depends on your plan’s tier, whether you receive Low-Income Subsidy (LIS), and how fast you hit the $2,100 annual cap.
| 2026 Standard Part D Benefit Phase | Your Cost for Tier 4 Drug* | Key 2026 Parameter |
|---|---|---|
| Deductible | 100% until met | $615 deductible(cms.gov) |
| Initial coverage | 25% coinsurance | Standard cost-sharing rate(cms.gov) |
| Post-cap catastrophic | $0 | $2,100 out-of-pocket threshold(cms.gov) |
*Exact tier and coinsurance vary by plan. Some plans charge a fixed copay instead of a percentage.
Manufacturer bridge programs can supply Zepbound free for up to 12 months if you have Medicare and face coverage delays. Check Lily’s official site for current terms and eligibility.
Step-by-Step: Improving Your Chances of Approval
The best time to fight for coverage is before you submit the prescription.
Gather rock-solid documentation: sleep study, weight history, CPAP compliance data, relevant comorbidities (hypertension, heart failure, daytime hypersomnolence).
Pre-submission checklist:
- Use the right ICD-10 codes: G47.33 for OSA and Z68.30-Z68.45 for obesity range.
- Note CPAP trial length: at least 90 consecutive days or documented intolerance.
- Confirm no drug exclusions: compare your plan’s 2026 formulary to make sure Zepbound is listed.
Coordinate with your prescriber’s prior-auth team: Most clinics have template letters of medical necessity that speed approval. Attach your Epworth Sleepiness Scale score if excessive daytime sleepiness is present.
What to Do if Medicare Denies Coverage
You have the right to appeal, and many denials are overturned at the first or second level. Follow these steps:
- Request the denial letter: it must state the reason and how to appeal.
- File a redetermination within 60 days: include any missing documents.
- Escalate to an Independent Review Entity (IRE): if the plan upholds the denial.
- Seek an ALJ hearing: for claims above $180 if the IRE also denies.
Is your Zepbound claim ready for submission?
Check the column that fits your situation:
✅ Good to go
- Sleep study confirms moderate-to-severe OSA
- BMI ≥ 30 kg/m² documented this year
- At least 90 days of CPAP trial or documented intolerance
- Prescription written by sleep or endocrinology specialist
- Prior-authorization form filled out completely
🏥 Fix before filing
- No recent sleep study or AHI < 15
- BMI below 30 kg/m² with no other qualifying condition
- CPAP never tried or trial shorter than 90 days
- Prescription written by primary-care only
- Missing clinical notes or lab values in PA packet
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe abdominal pain: could signal pancreatitis, a known GLP-1 risk.
- Persistent nausea or vomiting: dehydration may develop quickly.
- Rapid heartbeat or chest pain: may indicate cardiovascular stress.
- Signs of low blood sugar: sweating, dizziness, confusion.
- Difficulty breathing during sleep despite treatment: OSA may be worsening.
- Swelling of face, lips, or throat: possible allergic reaction.
- Thoughts of self-harm: call 988 Suicide & Crisis Lifeline or 911.
Scientific References
Frequently Asked Questions
Is Zepbound considered a protected class drug under Medicare?
No. Zepbound belongs to the GLP-1 receptor agonist class, which is not one of Medicare’s six protected classes. Plans can therefore exclude it or apply strict prior authorization.
Does Medicare Advantage cover Zepbound differently from stand-alone Part D?
Possibly. Medicare Advantage plans with built-in drug coverage use their own formularies, which may differ from stand-alone Part D plans. Always check the 2026 evidence of coverage for your specific MA-PD plan.
Can I use a manufacturer savings card with Medicare?
No. Federal law bars manufacturers from offering copay cards to Medicare beneficiaries. Lilly’s GLP-1 Bridge program, however, provides free medication for a limited time and is allowed because it is not a copay coupon.
Will Medicare cover Zepbound if I use it primarily for weight loss?
Coverage is likely to be denied unless you also meet the FDA-approved OSA criteria. Medicare does not generally cover drugs solely for weight-loss indications.
How long does prior authorization take?
Electronic prior authorization can be approved in as little as 24-72 hours if all documents are complete. Paper submissions may take 7-14 days.
Can my doctor appeal on my behalf?
Yes. Prescribers or their office staff usually file the appeal documents, but you must sign the request if the appeal goes beyond the first level.
What if Zepbound is not on my plan’s 2026 formulary?
You can request a formulary exception or switch to a Part D plan that lists the drug during the Medicare Open Enrollment Period (October 15-December 7).
